Stock Research for CLSN


Featured Broker: Ally Invest

Get the due diligence for another stock.


CLSN Stock Chart & Research Data

The CLSN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLSN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CLSN Due diligence Resources & Stock Charts

The CLSN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CLSN Detailed Price Forecast - CNN Money CNN View CLSN Detailed Summary - Google Finance
Yahoo View CLSN Detailed Summary - Yahoo! Finance Zacks View CLSN Stock Research & Analysis -

Stock Analysis

TradeIdeas View CLSN Trends & Analysis - Trade-Ideas Barrons View CLSN Major Holders - Barrons
NASDAQ View CLSN Call Transcripts - NASDAQ Seeking View CLSN Breaking News & Analysis - Seeking Alpha
Spotlight View CLSN Annual Report - OTC Report View CLSN OTC Short Report -
TradeKing View CLSN Fundamentals - TradeKing Charts View CLSN SEC Filings - Bar Chart
WSJ View Historical Prices for CLSN - The WSJ Morningstar View Performance/Total Return for CLSN - Morningstar
MarketWatch View the Analyst Estimates for CLSN - MarketWatch CNBC View the Earnings History for CLSN - CNBC
StockMarketWatch View the CLSN Earnings - StockMarketWatch MacroAxis View CLSN Buy or Sell Recommendations - MacroAxis
Bullish View the CLSN Bullish Patterns - American Bulls Short Pains View CLSN Short Pain Metrics -

Social Media Mentions

StockTwits View CLSN Stock Mentions - StockTwits PennyStocks View CLSN Stock Mentions - PennyStockTweets
Twitter View CLSN Stock Mentions - Twitter Invest Hub View CLSN Investment Forum News - Investor Hub
Yahoo View CLSN Stock Mentions - Yahoo! Message Board Seeking Alpha View CLSN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CLSN - Insider Cow View Insider Transactions for CLSN - Insider Cow
CNBC View CLSN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CLSN - OTC Markets
Yahoo View Insider Transactions for CLSN - Yahoo! Finance NASDAQ View Institutional Holdings for CLSN - NASDAQ

Stock Charts

FinViz View CLSN Stock Insight & Charts - StockCharts View CLSN Investment Charts -
BarChart View CLSN Stock Overview & Charts - BarChart Trading View View CLSN User Generated Charts - Trading View

Latest Financial News for CLSN

Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Posted on Thursday February 21, 2019

Celsion Corporation (CLSN), an oncology drug development company, today announced that on February 19, 2019, the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 140,004 shares of common stock and (ii) restricted stock grants (the “Inducement Stock Grants”) totaling 13,000 shares of common stock to two new employees. Each of the Inducement Option Grants has an exercise price per share equal to $2.18, the closing price of Celsion’s common stock as reported by Nasdaq on February 19, 2019.

Consolidated Research: 2019 Summary Expectations for Southwest Airlines, Southern Copper, SEI Investments, Forward Air, Cincinnati Financial, and Celsion — Fundamental Analysis, Key Performance Indications
Posted on Friday February 01, 2019

NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference
Posted on Thursday January 24, 2019

LAWRENCEVILLE, N.J., Jan. 24, 2019 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church, Celsion’s Executive Vice.

Celsion Announces Publication of ThermoDox® Study Results in Radiology
Posted on Thursday January 17, 2019

Celsion Corporation (CLSN), an oncology drug development company, today announced that results from the Phase I TARDOX trial of ThermoDox® conducted at the University of Oxford, United Kingdom, were published in the peer-reviewed journal, Radiology. The TARDOX trial evaluated the safety and efficacy of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer. The article, titled, “Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial,” included an evaluation of the TARDOX results and the safety, efficacy and utility of treatment with ThermoDox® plus targeted, non-invasive hyperthermic ultrasound in patients with solid liver tumors, with treatment plans based on patient-specific modeling.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.